An intra-patient placebo-controlled Phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma

IMM-101 is a heat-killed innate and adaptive immune-activating mycobacterial product; a phase I study aimed to determine its safety and tolerability in individuals with melanoma


Journal: Annals of Oncology

Author[s]: J. Stebbing, A. Dalgleish, A. Gifford-Moore, A. Martin, C. Gleeson, G. Wilson, L. R. Brunet, J. Grange & S. Mudan Date: 19 September 2011

DOI: 10.1093/annonc/mdr363

Click here to view paper